### Epigenetic Mechanisms in Autism Spectrum Disorders

Janine LaSalle, Ph.D Medical Microbiology and Immunology Rowe Program in Human Genetics UC Davis School of Medicine

### Autism and Epigenetics What's the connection?



# **Autism**



- Complex developmental disorder that usually appears in first three years of life
- Not a single disorder but a spectrum of neurodevelopmental disorders characterized by:
  - Impairments in social interactions and communication
  - Impairments in language
  - Restrictive and repetitive interests and behaviors

# **Autism**

- <u>Regressive autism</u>: apparently normal infancy followed loss of recpirocal social interactions, loss of language, gain of sterotypical behaviors around 18 mo to 4 years of age
- <u>Early onset autism:</u> no apparent loss of language or social interactions
- Male bias for autism 4:1; Asperger's 10:1

Autism most likely results from alterations in brain development and maturation due to a combination of genetic and environmental factors



## **Genetics of Autism**

- Strong genetic component to risk for autism:
  - Family studies: 50x greater risk for sibs of children with autism compared to the general population.
  - Identical twin studies
    MZ concordance = 60-90%
    DZ concordance = 0-10 %

 $- H^2 > 90\%$ 

But genetic basis is likely complex; multiple approaches are needed

# Loci identified by genome scans that might increase risk of autism



Nature Reviews | Genetics

Folstein and Rosen-Sheidley, 2001, Nature Reviews Genetics

### New mutations and copy number variations in autism



• The majority of autism cases are a result of *de novo* mutations, occurring first in the parental germ line.

• For reasons yet to be determined, female offspring are considerably more resistant to displaying the effects of such mutations than are males.

• Resistant individuals, but females in particular, carrying a mutation may marry and, with a probability of 50%, pass the mutation to their offspring, who will display the symptoms with high probability if male.

### Is autism prevalence on the rise?

### California's Developmental Services System Schechter and Grether, 2008



#### Associated milestones in the United States:

- \* 1991: Hib and hepatitis B virus vaccines recommended for infants and children
- † 1993: Licensure of first formulation of Hib vaccine (PRP-T) that contained no thimerosal
- ‡ 1999: Joint AAP-USPHS recommendation that thimerosal be removed as soon as possible from childhood vaccines
- § 2001: All new lots of routine childhood vaccines (other than influenza vaccine) contain no more than traces of thimerosal
- II 2002: Expiration dates for residual lots of routine childhood vaccines (other than influenza vaccine) that contain more than traces of thimerosal

### Is this an increase in diagnosis, prevalence, or both?

## **Rett Syndrome**

- Rett syndrome is the only one of the pervasive developmental disorders with a single known genetic cause
  - DSM IV Pervasive Developmental Disorders:
    - Autism
    - Asperger syndrome
    - Childhood disintegrative disorder
    - Rett syndrome
    - PDD-NOS

# **Rett Syndrome**

![](_page_10_Picture_1.jpeg)

- X-linked dominant, ~80% MECP2 mutation
- ~1/10,000 in US population
- Neurodevelopmental regression around 6 to 18 months of age
- MECP2 encodes a known epigenetic factor, methyl CpG binding protein 2

Rett syndrome involves epigenetics at 2 levels

### **Clinical Progression of Rett syndrome**

YEARS 0.5 1 2 3 4 5 10 20 >20
Normal development
Developmental stagnation Microcephaly Growth arrest Hypotonia
Rapid regression Autistic features
Loss of hand skills, speech, and social interaction
Hand stereotypies Mental retardation Motor abnormalities
Seizures
Respiratory abnormalities
Stationary stage Scoliosis
Autonomic dysfunction
Anxiety
Late motor deterioration Decrease/loss of mobility Parkinsonian features

Chahrour and Zoghbi, Neuron, 2007

# MeCP2 is a marker for mature neurons in the post-natal mammalian brain

![](_page_12_Picture_1.jpeg)

Sytox Green Anti-MeCP2

### MeCP2 appears to have multiple roles in regulating gene expression in neurons

![](_page_13_Figure_1.jpeg)

Activity dependent gene regulation

Regulation of alternative splicing

Chahrour and Zoghbi, Neuron, 2007

### Genetic and environmental interactions in regressive autism What Rett syndrome reveals

![](_page_14_Figure_1.jpeg)

Etiologic environmental exposures in autism could be causitive (thalidamide, valproate, Rubella), or additive to genetic susceptibility (likely to be more common)

Long-term effects from in utero exposures could alter epigenetic mechanisms, leading to behavior and cognitive dysfunction in the child and adult

# **Epigenetics**

### **DNA methylation**

![](_page_15_Figure_2.jpeg)

#### Chromatin structure

![](_page_15_Figure_4.jpeg)

Inherited and reversible modifications to nucleotides or chromosomes that do not change the sequence but can alter gene expression

#### **Histone modifications**

![](_page_15_Figure_7.jpeg)

# Spatial organization of chromosomes

![](_page_15_Picture_9.jpeg)

Interphase SH

![](_page_15_Picture_10.jpeg)

Kosak and Groudine, 2004

![](_page_16_Picture_0.jpeg)

### Examples of epigenetic mechanisms X chromosome inactivation

![](_page_16_Picture_2.jpeg)

Calico cats are females and are mosaics of cells expressing black and orange coat colors

![](_page_16_Figure_4.jpeg)

Figure 7–77. Molecular Biology of the Cell, 4th Edition.

### **Rett syndrome**

![](_page_16_Picture_7.jpeg)

Rett girls are mosaics of cells expressing mutant *MECP2* 

![](_page_17_Picture_0.jpeg)

### **Examples of epigenetic mechanisms**

### **Parental Imprinting**

![](_page_17_Figure_3.jpeg)

## **Epigenetics** <u>Examples of epigenetic mechanisms</u> Tissue-specific and developmental differences in gene expression

![](_page_18_Picture_1.jpeg)

Embryonic neuronal nucleus

Mature adult neuronal nucleus

![](_page_18_Picture_4.jpeg)

DNA dye (DAPI) of mouse cortical neurons

Figure 7–1. Molecular Biology of the Cell, 4th Edition.

# Examples of epigenetic mechanisms Environmental effects on gene expression

![](_page_19_Picture_1.jpeg)

### **Bisphenol A (BPA)**

![](_page_19_Picture_3.jpeg)

### Bisphenol A (BPA) + folic acid

![](_page_19_Picture_5.jpeg)

Dolinoy et al, PNAS, 2007

# Epigenetic disorders on the autism spectrum

- The imprinted disorders Prader-willi and Angelman syndromes are on the autism spectrum.
  - 2-42% of AS and PWS cases have comorbid autism, depending on study
  - Uniparental disomy cases of PWS may be more frequently autistic
- Maternal 15q11-13 duplications are the most common cytogenetic cause of autism (1-3%)

# Angelman and Prader-Willi syndromes

![](_page_21_Picture_1.jpeg)

Imprinted disorders caused by 15q11-13 deletions or deficiency (~1/20,000)

AS: Maternal 15q11-13 deletion, paternal disomy, maternal UBE3A mutation, imprinting defects

PWS: Paternal 15q11-13 deletion, maternal disomy, imprinting defects

![](_page_21_Picture_5.jpeg)

### Parental Imprinting and Mammalian Reproductive Technologies

- Many cloned livestock exhibit "large offspring syndrome" due to dysregulated expression of Igf2.
- Cloned mice and embryonic stem cells have many epigenetic defects in imprinted genes.
- Human ES cell lines exhibit altered methylation patterns compared to normal human tissue.
- Human children from in vitro fertilization (IVF) have increased rates of Angelman and Beckwith-Wiedemann syndromes.

The Rosetta Stone approach to "decoding" the complex genetics and epigenetics in autism

![](_page_23_Picture_1.jpeg)

![](_page_23_Picture_2.jpeg)

### Evidence for epigenetic overlap between autism, RTT, and AS

- MeCP2 expression is significantly reduced in 79% of autism post-mortem brain samples
- Methylation of the *MECP2* promoter correlates with reduced expression in male autism brain samples
- GABRB3 expression (15q11-13) is significantly reduced in 56% of autism post-mortem brain samples
- Biallelic expression levels of GABRB3 are epigenetically dysregulated in Rett and autism postmortem brain
- Homologous pairing of 15q11-13 in mature neurons is deficient in RTT, autism, and AS

![](_page_24_Picture_6.jpeg)

Ravi Nagarajan GGG student

![](_page_24_Picture_8.jpeg)

Amber Hogart GGG student

![](_page_24_Picture_10.jpeg)

Karen Thatcher GGG student

### MeCP2 binds to the imprinting control region of 15q11-13 and regulates UBE3A and GABRB3 expression

![](_page_25_Figure_1.jpeg)

ChIP-chip analysis of MeCP2 binding at *SNRPN* and 62 additional sites within 13 MB of 15q11-13 *Yasui et al., 2007* 

*MECP2* mutation or deficiency does not alter imprinted expression, but reduces levels of *UBE3A* and *GABRB3 Samaco et al, 2005* 

# Reduced MeCP2 in autism frontal cortex correlates with aberrant methylation

![](_page_26_Figure_1.jpeg)

Nagarajan et al, Epigenetics, 2006

### Identification of a methylation boundary element upstream of *MECP2* bound by CTCF

![](_page_27_Figure_1.jpeg)

Nagarajan et al, Autism Research, in revision

### GABRB3 expression positively correlates with MeCP2

![](_page_28_Figure_1.jpeg)

Significant correlation between MeCP2 and GABRB3 protein levels suggests that MeCP2 positively regulates *GABRB3* expression

## Nonimprinted *GABRB3* is epigenetically dysregulated in a subset of autism and Rett syndrome brains

![](_page_29_Figure_1.jpeg)

Hogart et al, Hum. Mol. Genet., 2007

### What is the future for epigenetics and autism?

Defining precise genetic and environmental risk factors and develop tests for precise epigenetic alterations

![](_page_30_Figure_2.jpeg)

Future directions examining environmental pollutants on epigenetics in neurodevelopment

BDE-47 PCB-95 GABRB3 MeCP2 Social behavior UBE3A Cognition Soizures

![](_page_31_Picture_2.jpeg)

Animal model component

*Меср2*<sup>308/+</sup> *Меср2*<sup>308/у</sup>

![](_page_31_Picture_5.jpeg)

![](_page_31_Picture_6.jpeg)

#### Human subject component

# Epigenetic interaction of MECP2 and organic pollutants in neurodevelopment

Perinatal exposure BDE-47

4 w prior/ 3 w in utero/ 3 w lactation

0.03 mg/kg/day 1 mg/kg/day vehicle control

![](_page_32_Picture_4.jpeg)

![](_page_32_Picture_5.jpeg)

C57BI6/J

![](_page_32_Picture_7.jpeg)

12 different treatment x genotype categories

X

*Mecp2*<sup>+/+</sup> *Mecp2*<sup>308/+</sup> *Mecp2*<sup>+/y</sup> *Mecp2*<sup>308/y</sup>

Test perinatally exposed mice for social and cognitive behavior Test mouse brains for epigenetic changes in MeCP2, UBE3A, global DNA methylation and histone modifications, etc

### **Behavioral Testing**

**Growth & Reflex Assessment** 

**Ultrasonic Vocalization Measurement** 

**Sociability Test** 

**Social Dyadic Interaction** 

**Acoustic Startle and Pre-Pulse Inhibition test** 

**Social Transmission of Food Preference** 

**Elevated Plus Maze** 

**Locomotor Activity Integra** 

**Spatial Memory and Learning in the Water Maze** 

### Preliminary evidence of epigenetic changes with perinatal BDE-47 exposure

![](_page_34_Figure_1.jpeg)

![](_page_35_Picture_0.jpeg)

CHILDHOOD AUTISM RISKS FROM GENETICS AND THE ENVIRONMENT

#### BeInCHARGE@ucdavis.edu

![](_page_35_Picture_3.jpeg)

#### Irva Hertz-Picciotto, PI

#### **Comprehensive, collaborative evaluation of autism**

- Medical evaluations
- Environmental exposures/epidemiology
- Behavior and neuropsychology
- Genomics
- Brain structure/imaging
- Immune function
- Epigenetics

#### **DNA** samples from four diagnostic categories

- Early onset autism
- Regressive autism
- Developmental delay
- Typically developing controls

Parental DNA also available

### **Epigenetic analyses on human samples**

### **CHARGE** blood DNA samples

- X chromosome inactivation
- DNA methylation at chromosome 15 imprinting control regions
- *MECP2* promoter methylation

### Human postmortem brain samples

- X chromosome inactivation
- DNA methylation at chromosome 15 imprinting control regions
- *MECP2* promoter methylation
- MeCP2 and GABRB3 expression

### Correlate epigenetic changes with PBDE tissue levels

### No evidence for X chromosome inactivation skewing differences between mothers of males with autism

	n=	number of uninformative samples (%)	avg age (y) <sup>a</sup>	avg small allele size (bp) <sup>a</sup>	avg large allele size (bp) <sup>a</sup>	avg % skewing <sup>a,b</sup>	inactive allele size (bp) <sup>a,c</sup>	% mothers with < 5% or > 95% skewing <sup>a</sup>	% mothers with < 15% or > 85% skewing <sup>a</sup>
Typical Development	23	5 (22)	33	274	286	53	280	11	17
Delayed Development	24	3 (13)	32	275	287	45	282	0	10
Autism	27	2 (7)	35	276	288	46	284	8	16
ASD	25	3 (12)	36	277	286	60	280	9	18

Notes:

<sup>a</sup> - for informative samples

<sup>b</sup> - percent of cells with small allele inactive

<sup>c</sup> - average of allele sizes (bp) of the alleles that are inactivated > 50%

#### Nagarajan et al, Autism Research, in revision

-

![](_page_37_Figure_7.jpeg)

PBDEs protective for XCI skewing?

#### Acknowledgements

LaSalle Lab **Dag Yasui** Susan Swanberg Mike Gonzales Karen Thatcher Sailaja Peddada Raman Nagarajan **Amber Hogart** Malaika Singleton **Christy Ballard Roxanne Vallero Katherine Patzel** Michelle Martin Haley Scoles **Joanne Suarez** Amy George **Brandon Woods** Stephanie Tring

<u>Collaborators, UCD</u> Isaac Pessah Irva Hertz-Picciotto Robert Berman Mari Golub Robin Hansen Judy Van de Water <u>Collaborators</u> Wendy Robinson, UBC Paul Kostiniak, U Buffalo

Financial Support NIH, 1R01 HD41462, 1R01 HD48799 1R01 ES015171

<u>Human tissue samples</u> CHARGE Autism Tissue Program, Maryland and Harvard Brain Banks